What New Zealand Medical & Scientific does

New Zealand Medical & Scientific Limited (operating as NZMS Diabetes) is a wholly-owned subsidiary of Dexcom, Inc., headquartered in Auckland, New Zealand. Founded in 1982, the company functions as the exclusive authorized distributor of Dexcom continuous glucose monitoring (CGM) systems and Tandem Diabetes Care insulin pumps in the New Zealand market, with a workforce of 101-250 employees. Its product portfolio centers on the Dexcom G7 and Dexcom ONE+ CGM systems (indicated for type 1, type 2, and gestational diabetes in patients aged 2 and older), the t:slim X2 insulin pump featuring Control-IQ+ and Basal-IQ automated insulin delivery algorithms, and supporting data management software (Dexcom Clarity, Glooko) and the Tandem t:slim Mobile App.

The company's business model is sales-led distribution of regulated medical devices to patients and healthcare professionals. Revenue is generated through hardware sales via a direct-to-consumer e-commerce storefront (shop.nzmsdiabetes.co.nz), phone ordering, and healthcare professional referrals (endocrinologists, diabetes educators, and GPs). The single most significant commercial development is the securing of Pharmac (New Zealand's pharmaceutical funding agency) reimbursement for Dexcom CGM in type 1 diabetes, a multi-year reimbursement decision that has materially expanded access to subsidized CGM. Marketing activities include a dedicated Healthcare Professional Portal and Education Hub, a Dexcom Warriors community program (20,000+ global members), nationwide events, and content marketing across owned digital channels. The company operates exclusively within New Zealand and does not disclose financials.

Name

New Zealand Medical & Scientific

Legal name

New Zealand Medical & Scientific Limited

Website

https://nzms.co.nz

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

101–250 employees

Short description

New Zealand Medical & Scientific is a wholly-owned Dexcom subsidiary distributing Dexcom continuous glucose monitoring systems and Tandem insulin pumps in New Zealand, serving patients with type 1, type 2, and gestational diabetes through e-commerce, HCP referrals, and Pharmac-funded reimbursement channels.

Ownership category

akta.pro rank

Product category

Diabetes Management Medical Devices

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)

akta.pro secondary industries

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Type 1 Diabetes Care (HLAKADAB), Type 2 Diabetes Care (HLAKADAC)

Keywords

• Diabetes management devices
• Continuous glucose monitoring
• Insulin pump therapy
• Medical device distribution
• Diabetes care products

Headquarters

HQ city

Auckland

HQ country

New Zealand

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Medical Device Sales: Sale of continuous glucose monitoring systems (Dexcom G7, Dexcom ONE+) and insulin pumps (t:slim X2) to patients and healthcare providers in New Zealand. Devices are sold through e-commerce and direct sales channels, with Pharmac funding available for eligible patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

NZMS Diabetes distributes Dexcom continuous glucose monitoring systems (G7 and ONE+) and Tandem t:slim X2 insulin pumps with Control-IQ+ and Basal-IQ technologies to patients across New Zealand. The offering is complemented by Dexcom Clarity and Glooko data management software, a mobile bolus app, and a healthcare professional education hub. Pharmac funding for Dexcom CGM in type 1 diabetes provides a government-subsidized access pathway.

Product overview

New Zealand Medical & Scientific distributes diabetes management products including Dexcom continuous glucose monitoring systems (G7 and ONE+) and Tandem t:slim X2 insulin pumps with Control-IQ+ and Basal-IQ technologies. The portfolio includes data management software (Dexcom Clarity and Glooko) for analyzing glucose data, a mobile app for pump control, and community support programs. The products work together as an integrated diabetes management ecosystem where CGM data feeds into insulin pump algorithms for automated insulin delivery adjustments.

Differentiator

Problem solved

Functional benefit

Products and services

• Dexcom G7 Continuous Glucose Monitoring System

Quantifiable outcome

• Dexcom CGM demonstrated better health outcomes in clinical studies (references: Beck RW et al. JAMA 2017; Beck RW et al. Ann Intern Med 2017; Martens T et al. JAMA 2021; Laffel LM et al. JAMA 2020; Welsh JB et al. J Diabetes Sci Technol 2024)

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• DexcomcoreOEM/ Whitelabel/ Licensing PartnerDexcom is the parent company of New Zealand Medical & Scientific Limited. NZMS operates as an authorized Dexcom subsidiary, distributing Dexcom CGM products (G7, ONE+) in New Zealand. The relationship provides exclusive distribution rights and access to Pharmac funding for Dexcom CGM devices.
• Tandem Diabetes CarecoreTechnology or IntegrationTandem Diabetes Care manufactures the t:slim X2 insulin pump with Control-IQ+ and Basal-IQ technologies. NZMS distributes Tandem insulin pumps in New Zealand as an authorized channel partner. Products include the t:slim X2 pump system that integrates with Dexcom CGM for automated insulin delivery.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ypsomed: Swiss manufacturer of the mylife YpsoPump and Loop AID ecosystem, increasingly distributed in Australia/NZ. Competes with the t:slim X2 in the patch/tubed pump category NZMS sells.
• LifeScan: Sells OneTouch blood glucose monitoring products and has explored CGM. Comparable as a diabetes-device vendor operating in NZ and competing for the same patient and HCP audience, particularly in the BGM/fingerstick segment.
• Abbott Diabetes Care: Markets the FreeStyle Libre family of CGM sensors, the most direct CGM competitor to Dexcom in NZ. Aggressive on price and consumer-friendly form factor, frequently the principal rival in Pharmac-style reimbursement tenders.

Others

• Glooko: Diabetes data management platform that NZMS bundles with its CGM and pump offerings. Comparable as an ecosystem enabler rather than a direct device competitor, and a candidate for deeper partnership or competitive substitution.

Broad incumbents

• Roche Diabetes Care: Sells Accu-Chek blood glucose monitoring systems and insulin pumps (e.g., Accu-Chek Insight) and has historically competed with CGM distributors in NZ. Relevant as a broad incumbent in the diabetes device category.
• Insulet: Maker of the OmniPod tubeless insulin pump with OmniPod 5 AID, integrating with Dexcom CGM. Directly competes for closed-loop pump share in the same patient population NZMS serves via Tandem.
• Medtronic: Global medtech incumbent that offers the Guardian CGM system and MiniMed insulin pump line directly competitive with NZMS's Dexcom CGM + Tandem pump stack. Sells in NZ and globally, often integrated in a single-vendor AID ecosystem (MiniMed 780G).
• Tandem Diabetes Care: Manufacturer of the t:slim X2 insulin pump and Control-IQ+ algorithm that NZMS distributes. While NZMS is a partner rather than a competitor, Tandem is a strategically comparable US-listed diabetes-device company focused on AID systems.

Emerging players

• Ascensia Diabetes Care: Markets the Eversense implantable CGM (through distribution) and Contour blood glucose meters. Relevant as an alternative CGM technology provider competing in the same patient segments NZMS targets.

Regional players

• AMSL Diabetes: Australia-based specialty diabetes distributor that historically distributed Dexcom CGM in Australia; structurally the closest ANZ peer to NZMS, sharing distribution model, regulatory pathway, and parent-brand relationship.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/nzmsdiabetes/events/?ref=page_internal

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New Zealand Medical & Scientific